Publications by authors named "R M Saraogi"

Introduction: Hypogonadism is a common comorbidity associated with several metabolic disorders including type 2 diabetes (T2D) that can remain undetected without proper screening. Here, we evaluated the prevalence of hypogonadism in Indian male patients with T2D with or without obesity.

Methods: In this prospective, observational study, male patients with T2D and hypogonadism were evaluated symptomatically using the androgen deficiency in ageing male (ADAM) questionnaire at baseline and confirmed on the basis of total testosterone (TT) levels (<300 ng/dL) at Days 5-7 (Visit 2) and 9-14 (Visit 4) assessed after 12 hours of fasting between 8 AM and 10 AM.

View Article and Find Full Text PDF

Background: Obesity, prediabetes, and type 2 diabetes mellitus (T2DM) pose a triple burden in India. Almost two-thirds of people with diabetes (PWD) in India are found to have suboptimal glycemic, blood pressure, and lipid control. Medical nutrition therapy (MNT) in diabetes has emphasized on the amount and type of carbohydrates for years.

View Article and Find Full Text PDF
Article Synopsis
  • 46, XY difference/disorder of sex development (DSD) involves varied degrees of underandrogenization in male genitalia, requiring a systematic diagnostic approach due to the lack of standardized clinical guidelines in some regions.
  • A consensus committee of 34 experienced endocrinologists drafted a comprehensive statement addressing diagnostic protocols, emphasizing thorough history taking, clinical examinations, and appropriate hormonal testing.
  • The recommended approach includes formal Karyotyping, tailored biochemical investigations based on age, ultrasound imaging, and utilizing both advanced and accessible hormone measurement techniques.
View Article and Find Full Text PDF

Diabetic kidney disease (DKD) occurs in approximately 20-40% of patients with type 2 diabetes mellitus. Patients with DKD have a higher risk of cardiovascular and all-cause mortality. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and antihyperglycemic drugs form the mainstay of DKD management and aim to restrict progression to more severe stages of DKD.

View Article and Find Full Text PDF